Lantern Pharma Receives EMA Clearance for LP-184 Bladder Cancer Trial in Europe

Lantern Pharma announced EMA clearance for a Phase 1b/2 trial of LP-184 in advanced bladder cancer, using biomarker-guided patient selection.